Summary

KEY FINDINGS
The global antibody drug conjugates contract manufacturing market is estimated to progress at a CAGR of 12.47% during the forecast period 2024-2032. Numerous aspects stimulate the market growth: the rising demand for targeted therapies, the growing inclination towards contract manufacturing companies as an economical choice, the surging global cancer incidence, and advancements in drug conjugation technologies.
MARKET INSIGHTS
The global antibody drug conjugates contract manufacturing market is experiencing significant growth driven by the rising demand for targeted cancer therapies and personalized medicine. ADCs represent a promising class of biopharmaceuticals that combine the specificity of monoclonal antibodies with the cytotoxicity of small-molecule drugs, offering enhanced efficacy and reduced side effects. This has led to increased research and development activities in the field of ADCs, creating a robust demand for contract manufacturing services.
Contract manufacturing organizations (CMOs) specializing in ADC production play a crucial role in supporting pharmaceutical companies in the development and commercialization of ADC therapies. These CMOs offer a range of services, including process development, scale-up, manufacturing, quality control, and regulatory support. Their expertise in bioconjugation techniques, linker chemistry, and analytical testing ensures the efficient production of high-quality ADCs meeting regulatory standards.
The global antibody drug conjugates contract manufacturing market is characterized by partnerships and collaborations between pharmaceutical companies and CMOs to leverage each other's strengths and capabilities. This collaboration model enables pharmaceutical companies to access specialized manufacturing expertise and infrastructure without substantial investments in building in-house ADC manufacturing capabilities. It also allows for flexibility in production scale, optimizing resources and reducing time-to-market for ADC therapies.
REGIONAL INSIGHTS
The global antibody drug conjugates contract manufacturing market growth analysis includes the geographical assessment of Asia-Pacific, Europe, North America, and Rest of World. North America is expected to be the eminent region in the global antibody drug conjugates contract manufacturing market. In the region, leading pharmaceutical companies such as AbbVie and Catalent, along with established CMOs, possess deep expertise in complex manufacturing processes, including ADCs. The region benefits from a strong biopharmaceutical supply chain, modern facilities, skilled labor, and government backing, driving growth in the ADCs contract manufacturing sector.
COMPETITIVE INSIGHTS
The global antibody drug conjugates contract manufacturing market exhibits intense rivalry among key players, driven by competition to offer advanced bioconjugation techniques, scalable production capacities, regulatory compliance, and cost-effective solutions. This competition fosters innovation, quality enhancements, and strategic partnerships to capture market share and meet the growing demand for targeted cancer therapies. Some of the eminent players in the market include Sterling Pharma Solutions, Recipharm AB, Lonza Group, Piramal Pharma Solutions, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. INCREASING COLLABORATION BETWEEN KEY CONTRACT MANUFACTURERS (CMOS)
2.5.2. CHALLENGES IN NAVIGATING COMPLEX REGULATORY REQUIREMENTS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. RISING DEMAND FOR TARGETED THERAPIES
3.1.2. GROWING INCLINATION TOWARDS CONTRACT MANUFACTURING COMPANIES AS AN ECONOMICAL CHOICE
3.1.3. SURGING GLOBAL CANCER INCIDENCE
3.1.4. ADVANCEMENTS IN DRUG CONJUGATION TECHNOLOGIES
3.2. KEY RESTRAINTS
3.2.1. HIGH COST OF ADC (ANTIBODY DRUG CONJUGATES) DEVELOPMENT AND MANUFACTURING
3.2.2. INCREASING COMPETITION FROM BIOSIMILAR ADC (ANTIBODY DRUG CONJUGATES) AND GENERIC DRUGS
3.2.3. STRINGENT REGULATORY REQUIREMENTS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. RISING DEMAND FOR ADCS
4.1.2. GROWING FOCUS ON ADC QUALITY AND REGULATORY COMPLIANCE
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR NORTH AMERICA
4.3.2. GROWTH PROSPECT MAPPING FOR EUROPE
4.3.3. GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC
4.3.4. GROWTH PROSPECT MAPPING FOR REST OF WORLD
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. KEY BUYING CRITERIA
4.6.1. EXPERTISE AND EXPERIENCE
4.6.2. MANUFACTURING CAPACITY
4.6.3. REGULATORY COMPLIANCE
4.6.4. QUALITY CONTROL
4.6.5. COST
4.7. REGULATORY FRAMEWORK
5. MARKET BY PHASE
5.1. CLINICAL PHASE
5.1.1. MARKET FORECAST FIGURE
5.1.2. SEGMENT ANALYSIS
5.2. COMMERCIAL PHASE
5.2.1. MARKET FORECAST FIGURE
5.2.2. SEGMENT ANALYSIS
6. MARKET BY LINKER
6.1. CLEAVABLE LINKERS
6.1.1. MARKET FORECAST FIGURE
6.1.2. SEGMENT ANALYSIS
6.2. NON-CLEAVABLE LINKERS
6.2.1. MARKET FORECAST FIGURE
6.2.2. SEGMENT ANALYSIS
7. MARKET BY CONDITION
7.1. MYELOMA
7.1.1. MARKET FORECAST FIGURE
7.1.2. SEGMENT ANALYSIS
7.2. LYMPHOMA
7.2.1. MARKET FORECAST FIGURE
7.2.2. SEGMENT ANALYSIS
7.3. BREAST CANCER
7.3.1. MARKET FORECAST FIGURE
7.3.2. SEGMENT ANALYSIS
7.4. OTHER CONDITIONS
7.4.1. MARKET FORECAST FIGURE
7.4.2. SEGMENT ANALYSIS
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
8.1.3. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
8.1.4. KEY PLAYERS IN NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
8.1.5. COUNTRY ANALYSIS
8.1.5.1. UNITED STATES
8.1.5.1.1. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.1.5.2. CANADA
8.1.5.2.1. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2. EUROPE
8.2.1. MARKET SIZE & ESTIMATES
8.2.2. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
8.2.3. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
8.2.4. KEY PLAYERS IN EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
8.2.5. COUNTRY ANALYSIS
8.2.5.1. UNITED KINGDOM
8.2.5.1.1. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.2. GERMANY
8.2.5.2.1. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.3. FRANCE
8.2.5.3.1. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.4. ITALY
8.2.5.4.1. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.5. SPAIN
8.2.5.5.1. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.6. SWITZERLAND
8.2.5.6.1. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.7. NORDIC COUNTRIES
8.2.5.7.1. NORDIC COUNTRIES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.2.5.8. REST OF EUROPE
8.2.5.8.1. REST OF EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3. ASIA-PACIFIC
8.3.1. MARKET SIZE & ESTIMATES
8.3.2. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
8.3.3. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
8.3.4. KEY PLAYERS IN ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
8.3.5. COUNTRY ANALYSIS
8.3.5.1. CHINA
8.3.5.1.1. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.2. JAPAN
8.3.5.2.1. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.3. INDIA
8.3.5.3.1. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.4. SOUTH KOREA
8.3.5.4.1. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.5. THAILAND
8.3.5.5.1. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.6. AUSTRALIA & NEW ZEALAND
8.3.5.6.1. AUSTRALIA & NEW ZEALAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.3.5.7. REST OF ASIA-PACIFIC
8.3.5.7.1. REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.4. REST OF WORLD
8.4.1. MARKET SIZE & ESTIMATES
8.4.2. REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
8.4.3. REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
8.4.4. KEY PLAYERS IN REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
8.4.5. REGIONAL ANALYSIS
8.4.5.1. LATIN AMERICA
8.4.5.1.1. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
8.4.5.2. MIDDLE EAST & AFRICA
8.4.5.2.1. MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.2. COMPANY PROFILES
9.2.1. ABBVIE INC (ABBVIE CONTRACT MANUFACTURING)
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. SERVICES LIST
9.2.1.3. STRENGTHS & CHALLENGES
9.2.2. CAMBREX CORPORATION
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. SERVICES LIST
9.2.3. CATALENT INC
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. SERVICES LIST
9.2.3.3. STRENGTHS & CHALLENGES
9.2.4. CERBIOS-PHARMA SA
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. SERVICES LIST
9.2.5. LONZA GROUP
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. SERVICES LIST
9.2.5.3. STRENGTHS & CHALLENGES
9.2.6. MERCK KGAA
9.2.6.1. COMPANY OVERVIEW
9.2.6.2. SERVICES LIST
9.2.6.3. STRENGTHS & CHALLENGES
9.2.7. PIRAMAL PHARMA SOLUTIONS
9.2.7.1. COMPANY OVERVIEW
9.2.7.2. SERVICES LIST
9.2.7.3. STRENGTHS & CHALLENGES
9.2.8. RECIPHARM AB
9.2.8.1. COMPANY OVERVIEW
9.2.8.2. SERVICES LIST
9.2.8.3. STRENGTHS & CHALLENGES
9.2.9. SARTORIUS AG
9.2.9.1. COMPANY OVERVIEW
9.2.9.2. SERVICES LIST
9.2.9.3. STRENGTHS & CHALLENGES
9.2.10. SAMSUNG BIOLOGICS CO LTD
9.2.10.1. COMPANY OVERVIEW
9.2.10.2. SERVICES LIST
9.2.10.3. STRENGTHS & CHALLENGES
9.2.11. STERLING PHARMA SOLUTIONS
9.2.11.1. COMPANY OVERVIEW
9.2.11.2. SERVICES LIST
9.2.11.3. STRENGTHS & CHALLENGES
9.2.12. WUXI BIOLOGICS
9.2.12.1. COMPANY OVERVIEW
9.2.12.2. SERVICES LIST
9.2.12.3. STRENGTHS & CHALLENGES